Table 1.
Characteristics and outcomes of the WCD patients.
| All patients (n=24) | Primary indication (n=11) | Secondary indication (n=13) | P value | |
|---|---|---|---|---|
| Age (years) | 69±12 | 67±11 | 76±3 | 0.59 |
| Male | 22 (92) | 9 (82) | 13 (100) | 0.20 |
| ST-elevated MI | 10 (42) | 1 (9.1) | 9 (69) | 0.0045 |
| Revascularized post-MI | 19 (79) | 9 (82) | 10 (77) | 1.0 |
| Median time from MI to WCD prescription (days) | 10 (5–31) | 6 (4–20) | 17 (7–38) | 0.19 |
| Median length of WCD use (days) | 33 (20–67) | 16 (29–56) | 29 (15–67) | 0.97 |
| Median daily use of WCD (h/day) | 23.1 (21.6–23.6) | 22.8 (20.0–23.2) | 23.3 (22.4–23.6) | 0.23 |
| LVEF before WCD therapy (%) | 30 (20–36) | 30 (18–34) | 32 (20–38) | 0.36 |
| LVEF after WCD therapy (%) | 35 (25–40) | 33 (30–38) | 43 (30–53) | 0.26 |
| WCD shock therapy | 2 (8.3) | 1 (9.1) | 1 (7.7) | 1.0 |
| Defibrillator implantation | 14 (58) | 4 (36) | 10 (77) | 0.095 |
The data are presented as mean±SD, number of patients (%), or median (25–75th percentile). WCD, wearable cardioverter defibrillator; MI, myocardial infarction; LVEF, left ventricular ejection fraction.